[The in vivo antitumor activity of murine liver tumor vaccine expressing MIP-1alpha].
OBJECTIVE
To observe the in vivo antitumor activity of murine liver tumor vaccine expressing MIP-1alpha mediated by recombinant adenoviral vector.


METHODS
The infection efficacy was measured by GFP expression 48 hours after infection of Hepa1-6, and the number of cells was counted daily for 14 days. 5 x 10(6) modified Hepa1-6 cells were inoculated subcutaneously to C57BL/6 mice and the tumor-free animals were rechallenged by 2 x 10(6) wild-type Hepa1-6 cells or syngenic EL4 cells four weeks later. The tumor volume was measured twice a week.


RESULTS
Adenoviral vectors could efficiently infect Hepa1-6 cells in vitro, and the in vitro growth rate of AdmMIP-1alpha modified Hepa1-6 cells was not affected; however the in vivo tumorigenicity was significantly decreased, compared with that of control vector modified Hepa1-6. Rechallenge of the tumor-free mice four weeks after administration of AdmMIP-1alpha with the parental Hepa1-6 cells resulted in significant inhibition of tumor growth, but there was no significant difference when rechallenged with EL4.


CONCLUSIONS
The liver cancer cells expressing mMIP-1alpha mediated by recombinant adenoviral vector decrease tumorigenicity and elicit specific immunological protection, and could be used as an effective liver tumor vaccine.
Yang
Qing
Q
Tumor Immunology and Biotherapy Center, Eastern Institute of Hepatobiliary Surgery, Second Military Medical University, Shanghai 200438, China.
Yang
Guangshun
G
Wei
Lixin
L
Jia
Fengqi
F
Wang
Weifeng
W
Wu
Mengchao
M
Guo
Yajun
Y
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D015316:Genetic Therapy; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D019402:Macrophage Inflammatory Proteins / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D014614:Vaccines, Synthetic / Q000276:immunology*
D019496:Cancer Vaccines; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins; D014614:Vaccines, Synthetic